{"id":20149,"date":"2026-02-09T11:04:03","date_gmt":"2026-02-09T11:04:03","guid":{"rendered":"https:\/\/microvibenews.com\/?p=20149"},"modified":"2026-02-09T11:04:03","modified_gmt":"2026-02-09T11:04:03","slug":"some-health-care-ceos-are-praising-trumprx-for-empowering-consumers-to-compare-drug-prices","status":"publish","type":"post","link":"https:\/\/microvibenews.com\/?p=20149","title":{"rendered":"Some health care CEOs are praising TrumpRx for empowering consumers to compare drug prices"},"content":{"rendered":"

<\/p>\n

Good morning<\/strong>. After months of waiting, the Trump administration last week launched TrumpRx.gov, a direct-to-consumer platform offering 43 brand-name prescription drugs with varying levels of discounts. I\u2019ve been talking to CEOs in all parts of the health care industry, from the drugmakers and insurers to those leading digital health platforms that now compete\u2014and cooperate with\u2014the new government site. \u201cIt\u2019s another platform that Americans can use to compare pricing,\u201d said Wendy Barnes, CEO of GoodRx, one of several platform partners with TrumpRx. \u201cAt present, I rate it positively from our perspective because it expands our reach and aligns with our mission.\u201d<\/p>\n

\n

So what\u2019s the takeaway for leaders looking at rising health care costs?<\/p>\n

It\u2019s probably not relevant to those who have insurance.<\/strong> Many of the listed prices are higher than what 92% of the U.S. population now pays because they have insurance, and the site excludes low-cost generic drugs. People on government plans probably aren\u2019t eligible to use the discounts. Moreover, the money spent on TrumpRx can\u2019t be counted toward an annual deductible or out-of-pocket maximum. Where it might save money: some fertility or GLP-1 drugs not covered by insurers.<\/p>\n

This won\u2019t impact Big Pharma\u2019s business model.<\/strong> No drugmaker is going to embrace a site that states: \u201cThanks to President Trump, the days of Big Pharma price-gouging are over.\u201d But as one CEO argued: \u201cWe\u2019ve negotiated similar prices with other DTC (direct-to-consumer) platforms. This is just another label.\u201d Many of the drugs are off-patent or already offered at deep discounts. What\u2019s not on the platform: Merck\u2019s lucrative Keytruda cancer drug, Bristol Myers Squibb\u2019s blood thinner Eliquis, Abbvie\u2019s Humira, Rinvoq and Skyrizi, as well as Dupixent, which is jointly developed by Regeneron and Sanofi. If there\u2019s a hero behind TrumpRx, it\u2019s Pfizer CEO Albert Bourla, whose company makes 31 of the 43 listed drugs.\u00a0\u00a0<\/p>\n

This could impact industry innovation.<\/strong> There are many arguments and ideas to bring more transparency, flexibility and consumer choice to the realm of drug pricing. Most involve removing regulatory obstacles to encourage innovation, not an executive order for a platform bearing Trump\u2019s name, which increases the likelihood that it will only last as long as his tenure. Existing platforms now have to compete for mindshare with a government rival. Also raising questions: TrumpRx\u2019s ties to vendor BlinkRx, where Donald Trump Jr. sits on the board.\u00a0That said, many applaud the effort as an important step in addressing rising health care costs. Said Barnes: \u201cI think just shining a spotlight on the idea that consumers do have power when it comes to shopping for drug pricing is a lesson that we\u2019re learning as Americans.\u201d<\/p>\n

Contact CEO Daily via Diane Brady at diane.brady@fortune.com<\/em><\/p>\n

Top leadership news<\/h3>\n

A Wall Street veteran makes waves at the Social Security Administration<\/b><\/p>\n

Wall Street veteran and Jamie Dimon prot\u00e9g\u00e9 Frank Bisignano is serving as Commissioner of the Social Security Administration as well as the first-ever CEO of the IRS. He <\/span>says<\/span> one of his biggest priorities has been to make the Social Security Administration more accessible and that his private sector experience has made a big difference so far.<\/span><\/p>\n

Meta\u2019s strategic Super Bowl ads<\/b><\/p>\n

Meta debuted two ads for its smart glasses during last night\u2019s Super Bowl, which likely cost the company between $8 million and $10 million apiece. One expert <\/span>argues<\/span> that the expensive move is also a play to convince consumers and investors of the company\u2019s AI future.<\/span><\/p>\n

Malaysia\u2019s economy minister says now is the time to invest in the country<\/b><\/p>\n

Malaysia\u2019s economy minister <\/span>told <\/span>Fortune<\/span><\/i> that this is \u201cthe best time to consider Malaysia as your [investment] destination\u201d before the Forum Ekonomi Malaysia summit last week. YB Akmal Nasrullah Mohd Nasir says the country\u2019s edge is its geopolitical neutrality and efforts in semiconductor manufacturing. <\/span><\/p>\n

The markets<\/h3>\n

S&P 500<\/b> futures were flat this morning. The last session closed up 1.97%. <\/span>STOXX Europe 600<\/b> was up 0.24% in early trading. <\/span>The U.K.\u2019s FTSE 100<\/b> was up 0.33% in early trading.<\/span> Japan\u2019s Nikkei 225<\/b> was up 3.89%<\/span>. China\u2019s CSI 300<\/b> was up 1.63%.<\/span> The South Korea KOSPI <\/b>was up 4.10%.<\/span> India\u2019s NIFTY 50<\/b> was up 0.67%.<\/span> Bitcoin<\/b> increased to $70K.<\/span><\/p>\n

Around the watercooler<\/h3>\n

In the AI era, Mark Cuban, Mary Barra, and even Sam Altman have one tip for Gen Z: unplug and go analog<\/span> by Preston Fore<\/span><\/p>\n

We may be looking at the housing affordability crisis all wrong. Higher earners are driving home prices, not lack of supply, researchers say<\/span> by Jason Ma<\/span><\/p>\n

Next-gen nuclear\u2019s tipping point: Meta and hyperscalers start deals with Bill Gates\u2019 TerraPower, Sam Altman-backed Oklo, and more<\/span> by Jordan Blum<\/span><\/p>\n

What caused the massive Bitcoin crash? Clues point to a blow-up at Hong Kong hedge funds<\/span> by Jeff John Roberts<\/span><\/p>\n

CEO Daily is compiled and edited by Joey Abrams, Claire Zillman and Lee Clifford.<\/p>\n<\/div>\n

#health #care #CEOs #praising #TrumpRx #empowering #consumers #compare #drug #prices<\/p>\n","protected":false},"excerpt":{"rendered":"

Good morning. After months of … <\/p>\n","protected":false},"author":1,"featured_media":20150,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[2175,451,526,1253,432,1027,2674,600,12312,397,12313],"_links":{"self":[{"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/posts\/20149"}],"collection":[{"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=20149"}],"version-history":[{"count":0,"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/posts\/20149\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=\/wp\/v2\/media\/20150"}],"wp:attachment":[{"href":"https:\/\/microvibenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=20149"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=20149"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/microvibenews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=20149"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}